Antiplatelet therapy: What have we learned from the ANTARCTIC trial?
Publication
, Journal Article
Gurbel, PA; Tantry, US
Published in: Nat Rev Cardiol
November 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Nat Rev Cardiol
DOI
EISSN
1759-5010
Publication Date
November 2016
Volume
13
Issue
11
Start / End Page
639 / 640
Location
England
Related Subject Headings
- Ticlopidine
- Platelet Aggregation Inhibitors
- Humans
- Cardiovascular System & Hematology
- Aspirin
- Aged
- Acute Coronary Syndrome
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Gurbel, P. A., & Tantry, U. S. (2016). Antiplatelet therapy: What have we learned from the ANTARCTIC trial? Nat Rev Cardiol, 13(11), 639–640. https://doi.org/10.1038/nrcardio.2016.167
Gurbel, Paul A., and Udaya S. Tantry. “Antiplatelet therapy: What have we learned from the ANTARCTIC trial?” Nat Rev Cardiol 13, no. 11 (November 2016): 639–40. https://doi.org/10.1038/nrcardio.2016.167.
Gurbel PA, Tantry US. Antiplatelet therapy: What have we learned from the ANTARCTIC trial? Nat Rev Cardiol. 2016 Nov;13(11):639–40.
Gurbel, Paul A., and Udaya S. Tantry. “Antiplatelet therapy: What have we learned from the ANTARCTIC trial?” Nat Rev Cardiol, vol. 13, no. 11, Nov. 2016, pp. 639–40. Pubmed, doi:10.1038/nrcardio.2016.167.
Gurbel PA, Tantry US. Antiplatelet therapy: What have we learned from the ANTARCTIC trial? Nat Rev Cardiol. 2016 Nov;13(11):639–640.
Published In
Nat Rev Cardiol
DOI
EISSN
1759-5010
Publication Date
November 2016
Volume
13
Issue
11
Start / End Page
639 / 640
Location
England
Related Subject Headings
- Ticlopidine
- Platelet Aggregation Inhibitors
- Humans
- Cardiovascular System & Hematology
- Aspirin
- Aged
- Acute Coronary Syndrome
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology